dc.contributor.author | Miller, A | |
dc.contributor.author | Carr, S | |
dc.contributor.author | Rabbitts, T | |
dc.contributor.author | Ali, H | |
dc.date.accessioned | 2020-09-03T11:22:25Z | |
dc.date.issued | 2020-01-01 | |
dc.identifier.citation | mAbs, 2020, 12 (1), pp. 1752529 - ? | |
dc.identifier.issn | 1942-0862 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/4058 | |
dc.identifier.eissn | 1942-0870 | |
dc.identifier.doi | 10.1080/19420862.2020.1752529 | |
dc.description.abstract | The success of therapeutic antibodies is largely attributed for their exquisite specificity, homogeneity, and functionality. There is, however, a need to engineer antibodies to extend and enhance their potency. One parameter is functional affinity augmentation, since antibodies matured in vivo have a natural affinity threshold. Generation of multivalent antibodies is one option capable of surpassing this affinity threshold through increased avidity. In this study, we present a novel platform consisting of an array of multivalent antibody formats, termed Quads, generated using the self-assembling tetramerization domain from p53. We demonstrate the versatility of this tetramerization domain by engineering anti-tumor necrosis factor (TNF) Quads that exhibit major increases in binding potency and in neutralizing TNF-mediated cytotoxicity compared to parental anti-TNF molecules. Further, Quads are amenable to fusion with different binding domains, allowing generation of novel multivalent monospecific and bispecific formats. Quads are thus a novel group of molecules that can be engineered to yield potential therapeutics with novel modalities and potencies. | |
dc.format | Print | |
dc.format.extent | 1752529 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | TAYLOR & FRANCIS INC | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
dc.title | Multimeric antibodies with increased valency surpassing functional affinity and potency thresholds using novel formats. | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1080/19420862.2020.1752529 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by-nc/4.0 | |
rioxxterms.licenseref.startdate | 2020-01 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | mAbs | |
pubs.issue | 1 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Chromosomal Translocations and Intracellular Antibody Therapeutics | |
pubs.publication-status | Published | |
pubs.volume | 12 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Chromosomal Translocations and Intracellular Antibody Therapeutics | |
dc.contributor.icrauthor | Rabbitts, Terence | |